By Inteledoc Expert Team | 10 min read |
If semaglutide (Ozempic/Wegovy) changed the conversation about medical weight loss, tirzepatide — sold globally as Mounjaro — has taken that conversation to an entirely new level. Clinical trial results showing average weight loss of over 20% of body weight in some patient groups have made Mounjaro the most searched weight loss medicine in the world. In India, the searches for “Mounjaro India” and “tirzepatide India” are rising fast. This blog answers every question about what it is, how it differs from semaglutide, whether it is available in India, and who should consider it.
What Is Tirzepatide (Mounjaro)? The Science Without the Jargon
Tirzepatide is a medicine that works on two natural hormone systems simultaneously — GLP-1 (Glucagon-Like Peptide 1) and GIP (Glucose-dependent Insulinotropic Polypeptide). Both of these hormones are produced naturally by your gut after eating. Both play important roles in signalling fullness to the brain, managing blood sugar, and influencing how the body stores and burns fat.
Previous GLP-1 medicines like semaglutide work on GLP-1 alone. Tirzepatide’s dual mechanism — acting on both pathways simultaneously — produces a stronger and more comprehensive effect on hunger, fullness, blood sugar regulation, and fat metabolism than GLP-1 alone. This is the biological reason why tirzepatide trial results have consistently exceeded semaglutide results across comparable patient populations.
Mounjaro is the brand name under which Eli Lilly markets tirzepatide. It has been approved in the USA, UK, and across Europe both for type 2 diabetes management and specifically for obesity treatment (under the brand name Zepbound in the US).
✗ COMMOM MISCONCEPTION
Mounjaro and Ozempic are basically the same medicine. If you have tried one, you know what the other will do.
They are related — both are injectable weekly medicines working through gut hormone pathways — but their mechanisms and clinical outcomes are meaningfully different. The SURMOUNT trials for tirzepatide showed average weight loss of 20.9% of body weight at the highest dose over 72 weeks — significantly greater than the STEP trials for semaglutide showed at 14.9% over 68 weeks. For patients for whom adequate response to semaglutide has not been achieved, tirzepatide may produce substantially better results.
Is Mounjaro / Tirzepatide Available in India?
As of 2026, tirzepatide is not yet formally approved by India’s CDSCO for domestic use. However, it has been available through specialist prescription in India — at dedicated obesity medicine and metabolic health clinics — as an imported medicine under appropriate regulatory frameworks. Access is currently limited but growing as regulatory approval progresses.
At Inteledoc, tirzepatide is assessed and prescribed for appropriate patients through our doctor-supervised programme, where clinical indication, patient profile, and access are reviewed together. The medicine is discussed at the initial consultation and prescribed only where it is the most appropriate clinical choice for that patient. See our programme plans and pricing here, and read our overview of how the Inteledoc assessment and prescription process works.
Mounjaro vs Wegovy — Which Is Better for Weight Loss?
Semaglutide (Wegovy/Ozempic)
Works on GLP-1 receptor alone. Average weight loss ~15% over 68 weeks in STEP trials. Well-established safety profile with 15+ years of clinical use. More widely available in India currently.
Tirzepatide (Mounjaro/Zepbound)
Works on GLP-1 + GIP receptors simultaneously. Average weight loss up to 20.9% over 72 weeks in SURMOUNT trials. Newer medicine with a strong but shorter clinical record. Currently more limited availability in India.
The question of which is better for a specific patient depends on their individual biology, clinical history, metabolic profile, and previous treatment response. This is a medical decision — not a consumer preference. Inteledoc’s doctors assess these factors individually and recommend the most appropriate medicine for each patient. Neither medicine is universally superior for all people.
Who Is Tirzepatide Right For in India?
Tirzepatide is most appropriately considered for adults with significant overweight or obesity (BMI 30 or above, or 27 or above with metabolic health conditions) who have not achieved adequate results with lifestyle modification and potentially previous GLP-1 treatment. It is particularly relevant for patients with significant insulin resistance, pre-diabetes, or type 2 diabetes — where the GIP mechanism provides additional metabolic benefit beyond weight loss alone.
It is also potentially appropriate as a first-line medical intervention for patients with more significant weight to lose or more complex metabolic profiles, where the stronger clinical efficacy data makes it the more appropriate starting point. Your Inteledoc doctor will make this assessment at your initial consultation based on your specific clinical picture.
✓ THE SAFETY REMINDER THAT CANNOT BE SKIPPED
Tirzepatide — like all GLP-1 class medicines — requires proper medical screening before prescription, careful dose titration starting from the lowest dose, and ongoing clinical monitoring. Purchasing from unregulated sources without medical oversight is dangerous. The clinical framework around the medicine is not optional — it is what makes the medicine both safe and effective.
What to Expect From Tirzepatide — A Realistic Timeline
Week 1-4 :
Starting dose of 2.5 mg weekly. Goal is safe adaptation, not rapid weight loss. Mild nausea is common and managed through dietary adjustment and dose timing guidance from your doctor.
Week 4-12 :
Dose increases gradually to 5 mg, then 7.5 mg, based on individual tolerance. Most patients notice significant appetite reduction by week six to eight. Weight loss begins moving steadily.
Weeks 12–36 :
Maximum effective dose reached (10mg or 15mg for appropriate patients). This is when the most significant weight loss occurs — combined with the dietary and lifestyle habits being built through the programme.
Beyond 36 Weeks :
Maintenance and consolidation phase. Results stabilised. Long-term programme plan established to maintain metabolic improvements and weight loss after active treatment.
Frequently Asked Questions
As an imported medicine, tirzepatide is currently at the premium end of GLP-1 medicine pricing in India — typically higher than semaglutide. Your Inteledoc doctor will discuss costs transparently at the initial consultation, including the total cost of medicine and programme. Contact us for current pricing.
Yes, within a properly supervised clinical programme. The SURMOUNT trial programme and subsequent real-world evidence have established a strong safety profile for tirzepatide. The most common side effects — nausea, reduced appetite, mild fatigue — are manageable through appropriate dose titration. Pre-treatment screening identifies the small subset of patients for whom it is contraindicated.
Yes, and this is a common clinical scenario for patients who have had a partial response to semaglutide and want to explore whether the dual mechanism of tirzepatide produces better results. The switch is managed by your doctor with appropriate dose timing and transition guidance.
Yes — tirzepatide was originally developed as a diabetes medicine and has demonstrated exceptional HbA1c reductions in diabetic patients alongside weight loss. For patients with both obesity and type 2 diabetes, it may address both conditions simultaneously more effectively than either a weight loss medicine or a diabetes medicine alone.
The first step is an initial medical consultation — available online from anywhere in India. Your doctor reviews your full clinical picture, discusses all available medicine options including tirzepatide, and recommends the most appropriate approach for your specific situation. Book your consultation here.
Regulatory processes are ongoing. Formal CDSCO approval for tirzepatide in India is anticipated, though precise timelines are subject to regulatory review. Access through specialist prescription pathways is currently available. Your doctor will keep you updated on the regulatory status as it evolves.
For many patients, tirzepatide produces weight loss outcomes that approach those of bariatric surgery — without the surgical risks, recovery period, or permanent anatomical changes. It is not appropriate for all patients, and for those with very severe obesity, surgery may still be the most appropriate option. Your doctor will advise based on your specific clinical profile.
Yes. Clinical evidence shows significant improvements in non-alcoholic fatty liver disease (NAFLD) with tirzepatide treatment — both through direct metabolic mechanisms and through the weight loss it produces. This is an additional benefit particularly relevant for the large proportion of overweight Indian adults who have co-existing fatty liver.
Ready to start your doctor-supervised weight loss journey?
Inteledoc — A Doctor-led, metabolonomics-informed medical weight loss program personalized to your unique metabolic profile. Online & in-person in Gurugram. Plans from ₹1,500/month.
Book a consultation